# US 2021/0330699 A1 · Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330699 A1 - Document ID: US20210330699A1 - Status: Published application - Kind: A1 - Application number: 16/856,766 - Filed: 2020-04-23 - Published: 2021-10-28 - Earliest claimed: 2020-04-23 - Assignees: Johnson & Johnson Consumer Inc., Skillman, NJ - Applicants: Johnson & Johnson Consumer Inc. - Inventors: Elizabeth Bruning; Kimberly Capone; Lisa Renee Gandolfi; Anthony Robert Geonnotti, III; Euen Thomas Ekman-Gunn; Diana Roshek Johnson; Frank J. Kirchner; Selina Moses; Delores Santora; Russel Walters; Frank C. Sun - Web page: https://patentgrep.com/patent/US20210330699A1 ## CPC - A61K 31/78: of acrylic acid or derivatives thereof - A61K 31/085: having an ether linkage to aromatic ring nuclear carbon - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - A61P 31/18: for HIV - A61P 31/20: for DNA viruses - A61P 31/22: for herpes viruses - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses, wherein said compositions further comprise less than about 9% by weight of surfactant having an HLB of greater than 12. ## Claims ### Claim 1 A method of inhibiting entry of enveloped viruses into cells comprising contacting said viruses with an anti-viral composition comprising at least one low molecular weight hydrophobically modified polymer in an amount effective to inhibit entry of viruses into cells, wherein said composition comprises less than about 9% by weight of surfactant. ### Claim 2 (depends on 1) A method according to claim 1 wherein said composition comprises between about 0.375% and 9% by weight of surfactant. ### Claim 3 (depends on 2) A method according to claim 2 wherein said composition comprises between about 0.375% and 6% by weight of surfactant. ### Claim 4 (depends on 2) A method according to claim 2 wherein said composition comprises between about 0.375% and 3% by weight of surfactant. ### Claim 5 (depends on 1) A method according to claim 1 wherein the TEP of said anti-viral composition is greater than about 3.8. ### Claim 6 (depends on 1) A method according to claim 1 further comprising applying said anti-viral composition to infectable surfaces of a subject. ### Claim 7 (depends on 1) A method according to claim 1 wherein said infectable surfaces comprise one or more of the group consisting of skin and mucosal tissue of a subject. ### Claim 8 (depends on 7) A method according to claim 7 wherein said mucosal tissue comprises tissue selected from the group consisting of oral tissue, ocular tissue, nasal tissue, vaginal tissue, or rectal tissue and a combination thereof. ### Claim 9 (depends on 1) A method according to claim 1 wherein said low molecular weight hydrophobically modified polymer comprises a polymer derived from at least one first monomeric component selected from the group consisting of (meth)acrylic acid and at least one second monomeric component selected from the group consisting of one or more C1 to C9 alkyl(meth)acrylates, wherein the low molecular weight copolymer has a number average molecular weight of about 100,000 or less. ### Claim 10 (depends on 1) A method according to claim 1 wherein said low molecular weight hydrophobically modified polymer is present in said composition in an amount of from about 0.00005% to about 3% percent by weight of the composition. ### Claim 11 (depends on 1) A method according to claim 1 wherein said composition further comprises at least 55% of water. ### Claim 12 (depends on 11) A method according to claim 11 wherein said composition comprises at least 97% of water. ### Claim 13 (depends on 1) A method according to claim 1 wherein said viruses are selected from the group consisting of poxviridae, herpesviridae, retroviridae Lentivirus and a combination thereof ### Claim 14 (depends on 13) A method according to claim 13 wherein said virus selected from the family of herpesviridae is herpes simplex virus 1, herpes simplex virus 2 or a combination thereof. ### Claim 15 (depends on 13) A method according to claim 13 wherein said virus selected from the family retroviridae Lentivirus is Human Immunodeficiency Virus 1. ### Claim 16 (depends on 1) A method according to claim 1 wherein said inhibition of virus entry into said cells results in the reduction of potential for viral infection. ### Claim 17 (depends on 1) A method according to claim 1 wherein the anti-viral composition does not substantially disrupt biological surfaces. ### Claim 18 A method of inhibiting enveloped viruses comprising contacting infectable surfaces with an anti-viral composition comprising at least one low molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells, wherein said composition comprises less than about 9% by weight of surfactant. ### Claim 19 (depends on 19) A method of inhibiting entry of enveloped viruses according to claim 19 further comprising contacting said viruses with said anti-viral composition. ### Claim 20 An anti-viral composition comprising at least one low molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells and at least 55% water, wherein said composition comprises less than about 9% by weight of surfactant. ### Claim 21 An anti-viral composition comprising at least one low molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells and at least 55% water, wherein said composition comprises from about 0.375% to about 9% by weight of surfactant having an HLB greater than 12. ### Claim 22 A method of inhibiting the transmission of viruses comprising applying to non-biological surfaces a composition comprising at least one low molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells wherein said composition comprises from about 0.375% to about 9% by weight of surfactant. ### Claim 23 A method of inhibiting the transmission of viruses comprising applying to ingestable surfaces a composition comprising at least one low molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells wherein said composition comprises from about 0.375% to about 9% by weight of surfactant. ### Claim 24 (depends on 20) A composition according to claim 20 wherein said composition comprises a dosage form selected from the group consisting of: a liquid, a lotion, a cream, a gel, a stick, a spray, a shaving cream, an ointment, a cleansing liquid wash, a solid bar, a shampoo, a paste, a powder, a mousse, a wipe, a patch, a wound dressing, an adhesive bandage, a hydrogel and a film. ### Claim 25 (depends on 20) A composition according to claim 20 wherein said hydrophobically modified low molecular weight polymer comprises a low molecular weight, non-crosslinked, linear acrylic copolymer derived from at least one first monomeric component selected from the group consisting of (meth)acrylic acid and at least one second monomeric component selected from the group consisting of one or more C1 to C9 alkyl (meth)acrylates, wherein the low molecular weight copolymer has a number average molecular weight of about 100,000 or less. ### Claim 26 (depends on 25) A composition according to claim 25 wherein said hydrophobically modified low molecular weight polymer is potassium acrylates copolymer. ### Claim 27 (depends on 26) A composition according to claim 26 wherein said composition further comprises from about 0.375% to about 9% by weight of surfactant selected from the group consisting of anionic, cationic, nonionic and amphoteric surfactants.